CXCL12 expression is predictive of a shorter time to tumor progression in low-grade glioma: A single-institution study in 50 patients

A. Salmaggi, M. Gelati, B. Pollo, C. Marras, A. Silvani, M. R. Balestrini, M. Eoli, L. Fariselli, G. Broggi, A. Boiardi

Research output: Contribution to journalArticle

Abstract

The clinical course of 50 patients with low-grade glioma (31 male, 19 female) undergoing surgery at a single Institution from 1992 to 1996 was analyzed in relationship with known prognostic factors as far as time to tumor progression (TTP) and survival time (ST) are concerned. Moreover, microvessel density (MVD) and expression of the angiogenesis-related chemokine CXCL12 were investigated in surgical specimens. Age at diagnosis ranged from 1 to 68 years (median 30). Histology revealed 11 fibrillary, 6 protoplasmatic, 5 gemistocytic astrocytoma, 18 oligoastrocytoma and 10 oligodendroglioma. Mean follow-up was 86 months. Four patients were lost to follow-up. Of the remaining 46, twenty-four have shown disease progression and 14 have died. Median overall survival was not achieved; an estimated 75% percentage of survivors was found at 78 months. Complete gross tumor removal was associated to a longer TTP (P = 0.04 logrank). Of the investigated immunohistochemical parameters, while MVD was not predictive of subsequent TTP, expression of CXCL12 was associated with a significantly shorter TTP (P = 0.01 logrank): this predictive value remained significant (P = 0.02) at multivariate analysis. The data suggest the possible prognostic value for CXCL-12 (an angiogenesis- and tumor-growth-related chemokine) on TTP in low-grade gliomas.

Original languageEnglish
Pages (from-to)287-293
Number of pages7
JournalJournal of Neuro-Oncology
Volume74
Issue number3
DOIs
Publication statusPublished - Sep 2005

Fingerprint

Glioma
Neoplasms
Microvessels
Oligodendroglioma
Chemokine CXCL12
Survival
Lost to Follow-Up
Astrocytoma
Chemokines
Survivors
Disease Progression
Histology
Multivariate Analysis
Growth

Keywords

  • CXCL12
  • Disease progression
  • Low-grade glioma
  • Microvessel density

ASJC Scopus subject areas

  • Cancer Research
  • Clinical Neurology
  • Oncology
  • Neuroscience(all)

Cite this

@article{815ac17754174c2d9cbb1a7f1595cbaf,
title = "CXCL12 expression is predictive of a shorter time to tumor progression in low-grade glioma: A single-institution study in 50 patients",
abstract = "The clinical course of 50 patients with low-grade glioma (31 male, 19 female) undergoing surgery at a single Institution from 1992 to 1996 was analyzed in relationship with known prognostic factors as far as time to tumor progression (TTP) and survival time (ST) are concerned. Moreover, microvessel density (MVD) and expression of the angiogenesis-related chemokine CXCL12 were investigated in surgical specimens. Age at diagnosis ranged from 1 to 68 years (median 30). Histology revealed 11 fibrillary, 6 protoplasmatic, 5 gemistocytic astrocytoma, 18 oligoastrocytoma and 10 oligodendroglioma. Mean follow-up was 86 months. Four patients were lost to follow-up. Of the remaining 46, twenty-four have shown disease progression and 14 have died. Median overall survival was not achieved; an estimated 75{\%} percentage of survivors was found at 78 months. Complete gross tumor removal was associated to a longer TTP (P = 0.04 logrank). Of the investigated immunohistochemical parameters, while MVD was not predictive of subsequent TTP, expression of CXCL12 was associated with a significantly shorter TTP (P = 0.01 logrank): this predictive value remained significant (P = 0.02) at multivariate analysis. The data suggest the possible prognostic value for CXCL-12 (an angiogenesis- and tumor-growth-related chemokine) on TTP in low-grade gliomas.",
keywords = "CXCL12, Disease progression, Low-grade glioma, Microvessel density",
author = "A. Salmaggi and M. Gelati and B. Pollo and C. Marras and A. Silvani and Balestrini, {M. R.} and M. Eoli and L. Fariselli and G. Broggi and A. Boiardi",
year = "2005",
month = "9",
doi = "10.1007/s11060-004-7327-y",
language = "English",
volume = "74",
pages = "287--293",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Springer New York LLC",
number = "3",

}

TY - JOUR

T1 - CXCL12 expression is predictive of a shorter time to tumor progression in low-grade glioma

T2 - A single-institution study in 50 patients

AU - Salmaggi, A.

AU - Gelati, M.

AU - Pollo, B.

AU - Marras, C.

AU - Silvani, A.

AU - Balestrini, M. R.

AU - Eoli, M.

AU - Fariselli, L.

AU - Broggi, G.

AU - Boiardi, A.

PY - 2005/9

Y1 - 2005/9

N2 - The clinical course of 50 patients with low-grade glioma (31 male, 19 female) undergoing surgery at a single Institution from 1992 to 1996 was analyzed in relationship with known prognostic factors as far as time to tumor progression (TTP) and survival time (ST) are concerned. Moreover, microvessel density (MVD) and expression of the angiogenesis-related chemokine CXCL12 were investigated in surgical specimens. Age at diagnosis ranged from 1 to 68 years (median 30). Histology revealed 11 fibrillary, 6 protoplasmatic, 5 gemistocytic astrocytoma, 18 oligoastrocytoma and 10 oligodendroglioma. Mean follow-up was 86 months. Four patients were lost to follow-up. Of the remaining 46, twenty-four have shown disease progression and 14 have died. Median overall survival was not achieved; an estimated 75% percentage of survivors was found at 78 months. Complete gross tumor removal was associated to a longer TTP (P = 0.04 logrank). Of the investigated immunohistochemical parameters, while MVD was not predictive of subsequent TTP, expression of CXCL12 was associated with a significantly shorter TTP (P = 0.01 logrank): this predictive value remained significant (P = 0.02) at multivariate analysis. The data suggest the possible prognostic value for CXCL-12 (an angiogenesis- and tumor-growth-related chemokine) on TTP in low-grade gliomas.

AB - The clinical course of 50 patients with low-grade glioma (31 male, 19 female) undergoing surgery at a single Institution from 1992 to 1996 was analyzed in relationship with known prognostic factors as far as time to tumor progression (TTP) and survival time (ST) are concerned. Moreover, microvessel density (MVD) and expression of the angiogenesis-related chemokine CXCL12 were investigated in surgical specimens. Age at diagnosis ranged from 1 to 68 years (median 30). Histology revealed 11 fibrillary, 6 protoplasmatic, 5 gemistocytic astrocytoma, 18 oligoastrocytoma and 10 oligodendroglioma. Mean follow-up was 86 months. Four patients were lost to follow-up. Of the remaining 46, twenty-four have shown disease progression and 14 have died. Median overall survival was not achieved; an estimated 75% percentage of survivors was found at 78 months. Complete gross tumor removal was associated to a longer TTP (P = 0.04 logrank). Of the investigated immunohistochemical parameters, while MVD was not predictive of subsequent TTP, expression of CXCL12 was associated with a significantly shorter TTP (P = 0.01 logrank): this predictive value remained significant (P = 0.02) at multivariate analysis. The data suggest the possible prognostic value for CXCL-12 (an angiogenesis- and tumor-growth-related chemokine) on TTP in low-grade gliomas.

KW - CXCL12

KW - Disease progression

KW - Low-grade glioma

KW - Microvessel density

UR - http://www.scopus.com/inward/record.url?scp=26844550853&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=26844550853&partnerID=8YFLogxK

U2 - 10.1007/s11060-004-7327-y

DO - 10.1007/s11060-004-7327-y

M3 - Article

C2 - 16132525

AN - SCOPUS:26844550853

VL - 74

SP - 287

EP - 293

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 3

ER -